ArticleSpectrochimica acta. Part A, Molecular and biomolecular spectroscopy2023
Sustainable Stability-Indicating spectra manipulations for the concurrent quantification of a novel Anti-COVID-19 drug and its active Metabolite: Green profile assessment.
Article in Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 10 citations in OpenAlex.
- Sustainable stability-indicating spectra manipulations for the concurrent quantification of gliclazide and its impurity A as the possible alkaline degradation product: Multi-Color Analytical Profile Assessment.Scientific reports · 2026Article
- Two chromatographic methods for analyzing paracetamol in spiked human plasma with its toxic metabolite, N-acetyl parabenzoquinone imine and its antidote, N-acetyl-L-cysteine.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Millions of individuals have lost their lives and changed their routines as a direct consequence of exposure to the coronavirus (Covid-19). Molnupiravir (MOL) is an orally bioavailable tiny molecule antiviral prodrug that is effective for curing the coronavirus that produces serious acute respiratory disorder (SARS-CoV-2). Fully green-assessed stability-indicating simple spectrophotometric methods have been developed and fully validated as per ICH criteria. The potential impact of degradation products of drug components on the safety and efficacy of a medication's shelf life is likely to be negligible. The field of pharmaceutical analysis necessitates various stability testing under different conditions. The conduct of such inquiries affords the prospect of predicting the most probable routes of degradation and ascertaining the inherent stability characteristics of the active drugs. Consequently, a surge in demand arose for the creation of an analytical methodology that could consistently measure the degradation products and/or impurities that may be present in pharmaceuticals. Herein, five smart and simple spectrophotometric data manipulation techniques have been produced for the concurrent estimation of MOL and its active metabolite as its possible acid degradation product namely; N-hydroxycytidine (NHC). Structure confirmation of NHC build-up through IR, MS and NMR analyses. All current techniques verified linearity ranging from 10 to 150 μg/ml and 10-60 μg/ml for MOL and NHC, respectively. The limit of quantitation (LOQ) values were in the range of 4.21-9.59 μg/ml, while the limit of detection (LOD) values were ranging from 1.38 - 3.16 μg/ml. The current methods were evaluated in terms of greenness by four assessing methods and confirmed to be green. The significant novelty of these methods depends on their being the first environmentally soundness stability-indicating spectrophotometric approaches for the concurrent estimation of MOL and its active metabolite, NHC. Also, the preparation of purified NHC delivers significant cost savings, instead of purchasing an expensive ingredient. These smart methods were utilized for analyzing the pharmaceutical dosage form which may be of great benefit to the pharmaceutical market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.